C- — FMP rating1. Form 4: 6 transactions1.
Quick AnswerAbbott Laboratories (ABT) Q4 consensus: revenue $13.2B1, EPS $1.641. 0 consecutive quarters of beat1.
Content generated by AI editorial engine. Written by Stock Expert AI's research desk with AI assistance. Figures come from FMP data and the official sources cited in the article.
The median of 10 price targets is $1201, stock is $104, +15.7% vs the analyst consensus median. Stock move on the next trading day: +2.0%.
C- — FMP rating1. Form 4: 6 transactions1.
Quick AnswerAbbott Laboratories (ABT) Q4 consensus: revenue $13.2B1, EPS $1.641. 0 consecutive quarters of beat1.
Next report
Watchlist
Q3 Growth Acceleration
Abbott's Q3 sales grew 7% and EPS grew 9%, an acceleration versus the first half of the year.
Robert Ford, CEO - Q3 FY26 Earnings Call - October 21, 2026Gross Margin Expansion
Adjusted gross margin reached 57.2% of sales, up 140 basis points from the prior year.
Philip Boudreau, CFO - Q3 FY26 Earnings Call - October 21, 2026Q4 Eps Guidance
Abbott guides Q4 adjusted EPS to a range of $1.62 to $1.67.
Philip Boudreau, CFO - Q3 FY26 Earnings Call - October 21, 2026Post Separation Profile
Excluding nutrition, Abbott expects sales growth to accelerate by 50 to 100 basis points and operating margin to rise by approximately 100 basis points.
"we would expect sales growth to accelerate by 50 to 100 basis points, gross margin as a percent of sales to increase by more than 200 basis points, and an operating margin as a percent of sales to increase by approximately 100 basis points."
- Philip Boudreau, CFO - Q3 FY26 Earnings Call - October 21, 2026
Nutrition Separation
Abbott plans to separate its nutrition business, with about $8.5 billion in annual sales, into an independent publicly traded company.
"With approximately $8.5 billion in annual sales, 16,000 employees, and 14 manufacturing sites, this will be the largest globally scaled pure-play company in the healthy nutrition market."
- Robert Ford, CEO - Q3 FY26 Earnings Call - October 21, 2026
Electrophysiology Acceleration
Electrophysiology growth is accelerating, with U.S. growth in the high teens and above 20% excluding LAA, driven by adoption of the Volt PFA catheter.
Robert Ford, CEO - Q3 FY26 Earnings Call - October 21, 2026Stock Expert AI - Methodology
Historical V1 earnings-model score (archived, Oct 24, 2026) — not the current MoonshotScore. Current MoonshotScore: ABT stock page
multi-pillar methodology. Revenue Growth and Cash Runway strong. Operating Leverage weak.
How is it calculated? ->6 investor frameworks. 1 bullish (Ray Dalio), 1 bearish (Ken Griffin), 4 neutral (Jim Simons, Klarman, Buffett, Munger).
How is it calculated? ->Quality business, trading at fair value.
How is it calculated? ->Past Performance
No RPO/backlog concentration disclosed in Q3 earnings call.
Form 4 Q3 FY26: 6 transactions, net -$45.75M1.
6 transactions · 4 sales / 2 purchases = net negative flow. Not large in absolute terms against a $179.4B market cap.
Not advice - a structural framework for earnings night. Decision discipline is yours.
Market Outlook
You read it in 5 minutes. When the numbers come out on Thursday evening - you know what you're looking at.
Data arrives at night. The framework is ready now.
Data arrives on Thursday evening. The framework is ready on this page: Q4 EPS threshold $1.641, CapEx threshold "below $399.0M". Two anchors, three scenarios.
Comparison Stock Expert AI is free today — no credit card.
Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts
Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing
Stock Expert AI is free today — no credit card. Council 6-lens analysis + MoonshotScore multi-pillar + Insider tracker + Technical levels - all in one platform, for every stock.
Educational tool, not investment advice. Past performance does not guarantee future results.
Calendar
DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.
This Abbott Laboratories (ABT) Q4 FY26 earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.
Abbott Laboratories (ABT): Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.
Abbott Laboratories (ABT): Figures are sourced from Financial Modeling Prep (FMP) fundamentals and consensus data plus official earnings-call transcripts; derived metrics are labeled with their source next to each figure.
Abbott Laboratories (ABT): No. This page is educational research, not investment advice. It summarizes analyst consensus and company data; consult a licensed financial advisor before making any investment decision.